A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma(POLARIS)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05016778
• Other study ID #: POLARIS
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: June 8, 2021
• Est. completion date: June 30, 2025

Study information

• Verified date: October 2022
• Source: Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The subject can understand and have the ability to sign an informed consent form;

2. Male or female subjects, aged 18-75 years;

3. The expected survival period is not less than 12 weeks;

4. ECOG score = 2 ;

5. Diagnosed as multiple myeloma according to the IMWG standard in 2018;

6. The expression of GPRC5D in bone marrow plasma cells is more than 20%, or it is positive in tumor tissue by immunohistochemistry. One of the following criteria must

be detected:

1. If IgG type MM, serum M protein =10g/L; if IgA, IgD, IgE or IgM type MM, serum M protein =5g/L;

2. Or urine M protein level =200mg/24h;

3. Or light chain type MM, serum free light chain (sFLC) = 100mg / L and K/ ? FLC ratio is abnormal;

4. Or there are extramedullary lesions;

7. Subjects who have received at least 3 different mechanism drugs (including chemotherapy, protease inhibitors, immunosuppressive agents, etc.) have failed treatments, or have progressed or recurred during the last treatment or within 6 months after the end of treatment ;

8. Lung function is normal, and oxygen saturation is greater than 92%;

9. No heart disease or coronary heart disease, echocardiogram showed normal diastolic function, left ventricular ejection fraction (LVEF) =50%, and no serious arrhythmia;

10. Liver function: TBIL<3×ULN, AST<2.5×ULN, ALT<2.5ULN;

11. Renal function: creatinine clearance rate (estimated by Cockcroft Gault formula) = 30 mL/min;

12. The blood routine meets the following standards:

1. Lymphocyte count>0.5×10e9/L;

2. Neutrophils =1.0×10e9/L;

3. Hemoglobin =80g/L;

4. Platelet =75×10e9/L

13. From the use of study drug to 2 years after treatment, male subjects or female subjects of childbearing age must agree and be able to take effective contraceptive measures.

Exclusion Criteria:

1. Pregnant or breastfeeding;

2. HBsAg or HBcAb are positive, and the quantitative detection of HBV DNA in peripheral blood is more than 100 copies / L; HCV antibody and HCV RNA in peripheral blood are positive; HIV antibody positive; Syphilis antibody is positive in the first screening;

3. Any unstable systemic disease: including but not limited to unstable angina, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification = grade III), severe arrhythmia with poor drug control, liver, kidney or metabolic diseases;

4. Had hypersensitivity or intolerance to any drug used in this study;

5. Patients who received anti-cancer chemotherapy or other medications within 2 weeks before screening;

6. Uncontrolled malignant tumors except MM, excluding malignant tumors that received radical treatment and no active disease was found within 3 years before enrollment;

7. Clinically significant central nervous system diseases, such as epilepsy, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, psychosis, active central nervous system involvement or cancerous meningitis;

8. In the past two years, autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) caused damage to terminal organs, or required systemic application of immunosuppressive or other drugs;

9. Severe active viral, bacterial or uncontrolled systemic fungal infections; Hereditary bleeding / coagulation diseases, history of non traumatic bleeding or thromboembolism, other diseases that may increase the risk of bleeding, etc;

10. Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening, or who plan to undergo ASCT during the study period;

11. Patients received allogeneic stem cell therapy;

12. Any unsuitable to participate in this trial judged by the investigator.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• GPRC5D-CAR-T
After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg,3×10e6/kg,6×10e6/kg.

Locations

Country	Name	City	State
China	The first affiliated hospital of medical college of zhejiang university	Hangzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
Zhejiang University	OriCell Therapeutics Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limited toxicity (DLT)	Dose limited toxicity	From date of initial treatment to Day 28 post GPRC5D CAR-T infusion.
Primary	AE and SAE	Adverse event and serious adverse event	From admission to the end of the follow-up, up to 2 years
Secondary	Concentration of CAR-T cells	In peripheral blood and bone marrow	From admission to the end of the follow-up, up to 2 years
Secondary	Objective Response Rate, ORR	Proportion of subjects with complete or partial remission	In 3 months of GPRC5D CAR-T cell infusion
Secondary	Disease control rate, DCR	The percentage of patients with remission and stable disease after treatment in the total evaluable cases.	From Day 28 GPRC5D CAR-T infusion up to 2 years
Secondary	Duration of remission, DOR	The time from the first assessment of remission or partial remission of the tumor to the first assessment of disease progression or death from any cause;	24 months post GPRC5D CAR-T cells infusion
Secondary	Progression-free survival, PFS	The time from cell reinfusion to the first assessment of tumor progression or death from any cause	24 months post GPRC5D CAR-Tcells infusion
Secondary	Overall survival, OS	The time from the cell reinfusion to death due to any cause.	From GPRC5D CAR-T infusion to death,up to 2 years